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ABSTRACT 
Objective: This study investigated the effect of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin-ii receptor blockers (ARBs) on 
protein creatinine index (PCI) of patients with hypertension in a standard care practice.  
Methods: This retrospective study was carried out in a tertiary hospital. Hypertensive patients were randomly selected and screened based on 
inclusion and exclusion criteria. PCI values were obtained from the patient’s medical record.  
Results: No significant differences were observed in the percentage of patients with proteinuria (PCI ≥20 mg/mmol creatinine) at pre-and post-
treatment among the patients treated with ACEI, ARB or non-ACEI/ARB. Patients treated with ACEI (-10 mg/mmol creatinine; IQR-37.5-+10; 
p<0.046) and ARB (-10 mg/mmol creatinine; IQR-30-+10; p<0.048) showed significant reduction in PCI values at post-treatment compared to the 
non-ACEI/ARB group (+5 mg/mmol creatinine; IQR 0-+32.5).  
Conclusion: Our findings demonstrated that standard care practice, the therapy of ACEI and ARB did not sufficiently reduce the number of patients 
with proteinuria but could reduce progression of the proteinuria. 
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INTRODUCTION 
A clinically significant presence of protein in the urine occurs due to 
the ineffectiveness of renal tubular reabsorption of albumin and small-
sized protein molecules [1]. Proteinuria refers to increased urinary 
excretion of albumin, other specific proteins, or total protein [2]. The 
severity of proteinuria is usually described as the amount of albumin 
present in the urine for example microalbuminuria or macro 
albuminuria, or as an index of protein to creatinine ratio (PCI).  
Proteinuria is an early sign and can be monitored for the 
progression of renal diseases [3]. Depending on age and ethnicity, 7 
to 40% of individuals with hypertension have proteinuria in a form 
of microalbuminuria [4]. Albuminuria is a well-known predictor of 
poor renal outcomes in patients with diabetes mellitus (DM) and 
hypertension [5]. The severity of proteinuria may also be a 
significant predictor of cardiovascular events in a population with 
DM nephropathy and hypertension [6, 7].  
Increased risk of cardiovascular events may be associated with 
increased levels of inflammatory markers or endothelial dysfunction 
which are commonly detected with high levels of proteinuria [8]. 
Improved epithelial function due to early blockade of the renin 
angiotensin aldosterone system (RAAS) may explain the mechanism 
of angiotensin converting enzyme inhibitors (ACEIs) and 
angiotensin II receptor blockers (ARBs) in reducing the risk for 
cardiovascular events. ACEIs and ARBs are effective in the treatment 
of hypertension. Well-designed clinical trials have demonstrated 
that both groups of agents are also able to preserve renal function in 
chronic kidney disease (CKD) and reduce proteinuria [9-14]. 
Nevertheless, the data on the effect of these agents on proteinuria in 
the standard care practice is limited. This study aimed to determine 
the changes of PCI in patients treated with ACEIs, ARBs or other 
antihypertensive agents in a routine standard care practice. 
MATERIALS AND METHODS 
This retrospective study was approved by the University 
Kebangsaan Malaysia Research Ethic Committee (UKM 
1.5.3.5/244/NF-005-2011). Medical records of patients who 
received hypertensive therapy between June 2008 and June 2010 
were reviewed and the data was analysed. The patients were not 
specifically recruited for any other clinical trial and the data in the 
medical records were from their routine scheduled visits to the 
medical clinic.  
A total of 1096 patients with hypertension were randomly identified 
from the Computerised Pharmacy Management System using the 
random number generator. All of these patients were screened 
according to the inclusion and exclusion criteria. Patients included in 
the analysis had at least 2 PCI readings; pre treatment PCI (pre-PCI) 
which was the reading of PCI within one month before the initiation 
of antihypertensive therapy and post treatment PCI (post-PCI) 
which was the reading of PCI after at least 3 mo on antihypertensive 
therapy. Average pre-or post-PCI reading was used in patients with 
more than one PCI reading. Patients with end stage renal failure and 
immune related nephropathy such as systemic lupus erythematosus 
diseases were excluded from the study. Based on these inclusion and 
exclusion criteria, 51 patients were identified as suitable subjects 
(ACEI group represented by 28 patients, ARBs group represented by 
15 patients and non-ACEI/ARB group represented by 8 patients). 
Major exclusion factor for the subjects was insufficient PCI data. 
The PCI readings were supplied by the Hospital’s Clinical 
Biochemistry Laboratory as part of the standard medical care 
monitoring parameters. PCI of less than 20 mg/mmol creatinine was 
classified as normo proteinuria and PCI of 20 mg/mmol creatinine 
and above was classified as proteinuria. Change in PCI (dPCI) was 
the difference between post-PCI and pre-PCI. The PCI was evaluated 
regardless of the dosage regimen and specific antihypertensive 
agent in the group. Patients who received ACEI or ARB were also 
allowed to receive other antihypertensive agents from other 
pharmacological classes. The direction of changes in PCI after the 
treatment was marked with the sign of negative (-) and positive (+) 
for reduction and increment in PCI, respectively. Parametric 
statistical tests were employed for continuous data that was 
normally distributed. Non-parametric statistical tests were 
employed for data that was nominal or ordinal in nature and 
continuous data with skewed distribution. Results are presented as 
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either number of items (n) with the percentage (%), mean with 
standard deviation (SD) or median with inter-quartile range (IQR).  
RESULTS 
The baseline characteristics of the patients are presented in table 1. 
None of the baseline characteristics were significantly different among 
the three treatment groups except for the systolic and diastolic blood 
pressures between the ACEI (median 151/83 mmHg) or ARB (median 
150/80 mmHg) treatment groups and the non-ACEI/ARB (median 
124/70 mmHg) treatment group (p<0.05). The ACEI group included 
patients treated with captopril (n = 1), enalapril (n = 11), imadapril (n 
= 3), perindopril (n = 10) and ramipril (n = 3).  
The ARB group included patients treated with irbesartan (n = 3), 
losartan (n = 6), telmisartan (n = 4) and valsartan (n = 2). The pre-
PCI readings among the treatment groups also showed no significant 
difference (p=0.123). 
 
Table 1: The characteristics of patients at baseline before antihypertensive therapy 
Characteristics Treatment group 
ACEI ARB Non-ACEI/ARB 
No. of patients 28 15 8 
Age, mean (SD) years 63.0 (7.7) 62.8 (5.9) 68.8 (8.3) 
Body Mass Index, mean(SD) kg/m 30.1 (5.2) 2 31.7 (5.7) 28.7 (4.8) 
Gender, n (%)    
Male 17 (60.7) 10 (66.7) 6 (75.0) 
Female 11 (39.3) 5 (33.3) 2 (25.0) 
Race, n (%)    
Malay 14 (50.0) 10 (66.7) 6 (75.0) 
Chinese 12 (42.8) 4 (26.7) 2 (25.0) 
Indian 1 (3.6) 1 (3.6) 0 (0.0) 
Others 1 (3.6) 0 (0.0) 0 (0.0) 
























Co-morbidities, no. of patients    
Hypertension 28 15 8 
Type II diabetes mellitus 25 13 8 
Ischemic heart disease 8 4 3 
Chronic kidney disease 22 14 8 
Hyperlipidemia 26 12 8 
Congestive heart failure 1 0 1 
Cerebrovascular disease 3 0 3 
Concurrent medication, no. of patients    
Diuretics 16 12 6 
Beta-blockers 18 12 6 
Calcium channel blockers 23 13 6 
Alpha-blockers 4 1 3 
Antiplatelets 19 10 6 
Insulin 20 12 5 
Statins 28 14 7 
Fibrates 8 10 3 
*One-way ANOVA with post hoc; Significant for ACEI versus non-ACEI/ARB or ARB versus non-ACEI/ARB; p<0.05., ACEI, angiotensin converting 
enzyme; ARB, angiotensin-II receptor blocker; SD, standard deviation; IQR = inter-quartile range.  
 
Based on the PCI 20 mg/mmol creatinine value as a cutting point for 
category of proteinuria, none of the treatment groups has shown 
significant changes between the pre-and post-proteinuria (ACEI 
group, p=0.956; ARB group, p=0.585; non-ACEI/ARB group, 
p=0.144). The median duration between the pre-PCI and post-PCI 
readings was 16 mo (IQR 9 to 21 mo). The dPCI before and after the 
treatment are presented in fig. 1. The dPCI for the ACEI group was-
10 mg/mmol creatinine (IQR-37.5 to+10), for the ARB group was-10 
mg/mmol creatinine (IQR-30 to+10) and for the non-ACEI/ARB 
group was+5 mg/mmol creatinine (IQR 0 to+32.5). No significant 
different in dPCI was demonstrated between the ACEI and ARB 
groups (p=0.766). Marginal differences in dPCI were demonstrated 
between ACEI and non-ACEI/ARB groups (p<0.046), and between 
ARB and non-ACEI/ARB groups (p<0.048).  
DISCUSSION 
Several methods to describe proteinuria have been established [2]. 
Among others, PCI and albumin creatinine ratio are consideration as 
quantitative measures of proteinuria. These tests should be done within 
3 mo of a positive dipstick test. The advantage of using PCI include 
corrected to the variation of urine concentration due to abnormal 
hydration and inconsistent protein excretion rate at different times 
during the day [2]. Accordingly, in this study, the PCI was employed as 
the quantitative measure of proteinuria before and after the treatment. 
Protein molecules which pass through the glomerular loops into the 
urine will be reabsorbed by active transport mechanisms in the 
proximal tubule. This reabsorption process has a limited capacity. If 
the amount of proteins exceeds this capacity, a pathologic proteinuria 
will develop. Conditions such as hypertension and hyperglycemia state 
may exacerbate the severity of proteinuria [15]. Other than being a 
marker for the risk of renal disease, protein in the urine also 
contributes to kidney damage. Proteins are toxic to the renal tubular 
cells and cause tubulointerstitial inflammation and scarring [16]. 
Several clinical trials have demonstrated the effects of ACEIs and 
ARBs on reducing proteinuria [9-14]. Nevertheless, in the current 
study, the effect of both agents in reducing proteinuria status was 
not established. Based on the category of proteinuria with a cut-off 
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point of 20 mg/mmol creatinine, all treatment groups did not show 
any significant improvement in the number of patients without 
proteinuria.  
However, this may not necessarily indicate that ACEI or ARB do 
not play an important role in the management of hypertensive 
patients with proteinuria. The findings may however indicate 
that both groups of agents have the capacity to prevent the 
progression of proteinuria.  
The risk to develop end-stage renal failure may be reduced if the 
overt proteinuria progression can be stopped [17]. 
 
 
Fig. 1: Changes in protein creatinine index at post treatment among antihypertensive treatment groups.  Shape represents the median; 
horizontal bold line represents the inter-quartile range; ACEI, angiotensin converting enzyme; ARB, angiotensin-II receptor blocker 
 
It is imperative to be aware that the evaluation of proteinuria based 
on a cut-off point may conceal the moderate yet beneficial effect of 
ACEIs and ARBs. Based on the PCI readings, there was a significant 
reduction in the amount of protein in the urine of patients treated 
with ACEI or ARB as compared to patients treated with non-
ACEI/ARB antihypertensive agents. This supports the ability of ACEI 
and ARB in preventing overt progression of proteinuria. The effects 
demonstrated in previously published well-designed clinical trial 
were evidently replicated in the current study. In patients with 
hypertension and hyperglycemia, the activation of RAAS can worsen 
the glomerulus capillary hypertension [15]. This condition increases 
glomerulus permeability and protein filtration to the urine. ACEIs 
and ARBs reduce the intra glomerular pressure by inhibiting the 
angiotensin II-mediated efferent arteriolar vasoconstriction. This 
may explains the greater reduction in proteinuria by ACEIs and 
ARBs. The specific renoprotective effect of the ACEIs and ARBs may 
be more pronounced than the antihypertensive effects especially in 
patient with diabetic nephropathy [18]. The control of hypertension 
in this population is usually achieved with combination therapy with 
other group antihypertensive agents such as calcium channel 
blockers and diuretics. Baseline blood pressure was significantly 
lower in the non-ACEI/ARB group compared to ACEI or ARB groups. 
Based on this baseline blood pressure, it was not expected that the 
non-ACEI/ARB group will progress to the worsening of protenuria 
status. However, our findings contradicted with our expectation. 
This grossly supported the advantages of employing ACEI or ARB in 
hypertension management.  
The current study findings have highlighted the important of ACEI and 
ARB in the management of hypertension with proteinuria, nevertheless 
the findings should be deduced with caution due to several limitations. 
The limited sample size, amount of medication dose, other medications 
that may affect the protein levels and intra-individual variability in the 
urine protein levels may have influenced indirectly the findings. Number 
of patients on ACEI or ARB therapy at screening was large, however, the 
monitoring of pre-and post-treatment urine protein was not routinely 
carried out for majority of this patients in the standard care practice. 
Thus, this affected the sample size. 
In conclusion, although ACEIs and ARBs did not improve the number 
of patients without proteinuria, the effects of both agents in 
preventing progression of overt proteinuria have been 
demonstrated in the standard care practice. 
CONFLICT OF INTERESTS 
Declared none 
REFERENCES 
1. Wittmann I, Molnár GA, Degrell P, Wagner Z, Tamaskó M, Laczy 
B, et al. Prevention and treatment of diabetic nephropathy. 
Diabetes Res Clin Prac 2005;68:S36-42.  
2. National Kidney Foundation. K/DOQI Clinical practice guideline 
for chronic kidney disease: evaluation, classification and 
stratification. Am J Kidney Dis 2002;39:S1-299. 
3. Keane WF, Eknoyan G. Proteinuria, albuminuria, risk, 
assessment, detection, elimination (PARADE): a position paper 
of the national kidney foundation. Am J Kidney Dis 
1999;33:1004-10. 
4. Jones CA, Francis ME, Eberhardt MS, Chavers B, Coresh J, 
Engelgau M, et al. Microalbumnuria in the US population: third 
national health and nutrition examination survey. 
Am J Kidney Dis 2002;39:445-59.  
5. Berrut G, Bouhanick B, Fabbri P, Guilloteau G, Bled F, Le Jeune 
JJ, et al. Microalbuminuria as a predictor of a drop in 
glomerular filtration rate in subjects with non-insulin-
dependent diabetes mellitus and hypertension. Clin Nephrol 
1997;48:92-7. 
6. Valmadrid CT, Klein R, Moss SE, Klein BE. The risk of 
cardiovascular disease mortality associated with 
microalbuminuria and gross proteinuria in persons with older-
onset diabetes mellitus. Arch Intern Med 2000;160:1093-100.  
7. Anavekar NS, Gans DJ, Berl T, Rohde RD, Cooper W, Bhaumik A, 
et al. Predictors of cardiovascular events in patients with type 2 
diabetic nephropathy and hypertension: a case for albuminuria. 
Kidney Int Suppl 2004;92:S50-5. 
8. Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Nijpels G, 
Dekker JM, et al. C-reactive protein and soluble vascular cell 
adhesion molecule-1 are associated with elevated urinary 
albumin excretion but do not explain its link with 
cardiovascular risk. Arterioscler Thromb Vasc Biol 
2002;22:593-8. 
9. Melbourne Diabetic Nephropathy Study Group. Comparison 
between perindopril and nifedipine in hypertensive and 
normotensive diabetic patients with microalbuminuria. Br Med 
J 1991;302:210-6.  
Bakry et al. 
Int J Pharm Pharm Sci, Vol 7, Issue 11, 40-43 
 
43 
10. Esnault VL, Brown EA, Apetrei E, Bagon J, Calvo C, DeChatel R, 
et al. The effects of amlodipine and enalapril on renal function 
in adults with hypertension and nondiabetic nephropathies: A 
3-year, randomized, multicenter, double-blind, placebo-
controlled study. Clin Ther 2008;30:482-98. 
11. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, 
Andersen S, Arner P. The effect of irbesartan on the 
development of diabetic nephropathy in patients with type 2 
diabetes. N Eng J Med 2001;345:870-8.  
12. Viberti G, Wheeldon NM. Microalbuminuria reduction with 
valsartan in patients with type 2 diabetes mellitus: a blood 
pressure-independent effect. Circulation 2002;106:672-8. 
13. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, 
Shahinfar S, et al. Albuminuria, a therapeutic target for 
cardiovascular protection in type 2 diabetic patients with 
nephropathy. Circulation 2004;110:921-7. 
14. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, 
Mogensen CE, et al. Reduction in albuminuria translates to 
reduction in cardiovascular events in hypertensive patients: 
losartan intervention for endpoint reduction in hypertensive 
study. Hypertension 2005;45:198-202.  
15. Remuzzi G, Bertani T. Pathophysiology of progressive 
nephropathies. N Eng J Med 1998;339:1448-56. 
16. Abbate M, Benigni A, Bertani T, Remuzzi G. Nephrotoxicity of 
increased glomerular protein traffic. Nephrol Dial Transplant 
1999;14:304-12. 
17. Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori 
M, et al. Renoprotective properties of ACE-inhibition in non-
diabetic nephropathies with non-nephrotic proteinuria. Lancet 
1999;354:359-64. 
18. Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, 
Keane WF, et al. Albuminuria is a target for renoprotective 
therapy independent from blood pressure in patients with type 
2 diabetic nephropathy: Post hoc analysis from the reduction of 
end points in NIDDM with angiotensin II antagonist Losartan 
(RENAAL) trial. J Am Soc Nephrol 2007;18:1540-6. 
 
